AbbVie Inc. (ABBV)

86.98
NYSE : Health Technology
Prev Close 86.72
Day Low/High 86.78 / 87.71
52 Wk Low/High 62.66 / 92.99
Avg Volume 7.69M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 128.24B
EPS 3.70
P/E Ratio 38.04
Div & Yield 4.72 (4.91%)
Shire Proposes $30B Deal to Buy Disease Specialist Baxalta

Shire Proposes $30B Deal to Buy Disease Specialist Baxalta

Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.

Price Isn't a Problem for Gilead Sciences

Price Isn't a Problem for Gilead Sciences

Drugmaker has one of the best showings of earnings season.

Price Isn't a Problem for Gilead Sciences

Price Isn't a Problem for Gilead Sciences

Drugmaker has one of the best showings of earnings season.

Avoid Gilead Shares for Now

Avoid Gilead Shares for Now

Competition and lower earnings cloud its future.

What to Watch Friday: American Airlines Earnings, New Home Sales

What to Watch Friday: American Airlines Earnings, New Home Sales

For Friday July 24, TheStreet awaits quarterly financial results from Biogen (BIIB), AbbVie (ABBV), American Airlines Group (AAL), and Spirit Airlines (SAVE).

How to Navigate This Week's Earnings Minefield

Don't make a learning week a gambling week.

What to Watch in the Week Ahead: Apple Earnings, Housing Data

What to Watch in the Week Ahead: Apple Earnings, Housing Data

For the week of July 20, TheStreet outlines the key earnings reports and economic data to watch on Wall Street.

Looking for the Next Receptos Is Plain Stupid Right Now

Looking for the Next Receptos Is Plain Stupid Right Now

These stocks will be up so high today, that many fans will say "no thanks."

The Stock Market Is Treacherous, Perilous, and Ultra-Rewarding

The Stock Market Is Treacherous, Perilous, and Ultra-Rewarding

This market is almost entirely special situation.

3 Dividend Hikes This Week You Should Know About

3 Dividend Hikes This Week You Should Know About

Duke Energy's recent increase puts its payout at the high end of the industry range.

'GILDed Age' Is Over for Gilead Shares

The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.

Biotech Moves Are Anything But Crazy

New companies are coming up with major drugs.

AbbVie Is Knocking on the Door Again

AbbVie Is Knocking on the Door Again

The ABBV chart looks constructive, with solid volume and bullish indicators.

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.

Deluge of Deals Isn't About to Dry Up

Acquisitions cut into overabundance of companies.

3 Biotechs That Are Worth Buying

Many of these stocks are off to the races.

3 Reasons Not to Be Gloomy About the Stock Market

With a weak dollar, calm oil and tame rates, we're doing fine.

Galapagos Drug in Partnership With AbbVie Looks to Replace HUMIRA

Galapagos Drug in Partnership With AbbVie Looks to Replace HUMIRA

Galapagos (GLPG) is the latest biotech stock to list on the Nasdaq Market with an impressive first day of trading as the stock traded up 20%.

You Can Almost Smell the Euphoria

The market is a very happy place these days, so be careful.

3 Fantastic Pharmaceutical Stocks: Abbvie, Vertex and Biogen

3 Fantastic Pharmaceutical Stocks: Abbvie, Vertex and Biogen

AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.

Janet Yellen, Stock Market Commentator?

It's not the Fed chief's place.

Despite Turmoil, Good Buys Still Exist

Despite Turmoil, Good Buys Still Exist

Drug makers, Apple and other tech stocks among reasonable bargains.

Apple and Gilead on the Earnings Clock

Apple and Gilead on the Earnings Clock

What to expect and focus on when these two report this week.

Until Next Time ...

The market was a slow-rolling melt-up today as Nasdaq closed at all-time highs and the S&P 500 closed above all-time levels, but just barely. The Russell 2000 underperformed today. Although the indices did not see much movement, there were some big ...

I'm Going to Keep Riding These Horses

Biogen miss no reason to abandon big 4 of Big Pharma.

Gilead May Be the Cure for the Blues

Gilead May Be the Cure for the Blues

Gilead's Relative Strength Index slope is very strong.

Gilead May Be the Cure for the Blues

Gilead May Be the Cure for the Blues

Gilead's Relative Strength Index slope is very strong.

Abbvie upgraded at BMO